Neostigmine is used to treat myasthenia gravis, a condition where muscles become weak and tired easily, and to reverse the effects of certain anesthesia drugs after surgery.[1] Prostigmin is currently being investigated across 11 indications[3], with its most advanced program in Phase 3.[1]
Prostigmin is one of 187 small molecule programs targeting Glaucoma. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
96 competitors in Liver Transplant
Prostigmin
Darbepoetin
Prothrombin Complex Concentrate
Rezzayo
Tacrolimus Pill
Octreotide
Lenvima
Beyfortus
Myfortic
Cyklokapron
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details